In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Danaher Corp.

http://www.danaher.com

Latest From Danaher Corp.

Deals in Depth August 2023

In the top August alliance by deal value, Precision BioSciences licensed Imugene global rights to azercabtagene zapreleucel (azer-cel), its lead allogeneic anti-CD19 CAR T candidate for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future. Precision will receive $21m up front and is eligible for $8m upon successful completion of the Phase Ib dosing in the CAR T relapsed LBCL patient population. For azer-cel, Precision is eligible to receive up to $198m in additional milestone payments plus royalties. For each additional research program selected by Imugene, Precision is eligible for up to $145m in milestone payments and tiered royalties on net sales.

Deals Financing

Danaher To Acquire Abcam For About $5.7Bn, Expand Services For Life-Science Industry

After a summer of speculation about who will close the deal with Abcam, tech leader Danaher came out ahead and will acquire Abcam for $24 a share.

M & A In Vitro Diagnostics

Medtech 100: Big Three Companies Lead From The Front With Medtech Back On Solid Growth Footing

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Medtech 100 Commercial

Big Three Lead From The Front With Medtech Back On Solid Growth Footing

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Outlook 2023 Sales & Earnings
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Medical Devices
  • Research, Analytical Equipment & Supplies
  • Other Names / Subsidiaries
    • Beckman Coulter
    • Cepheid
    • Cytiva
    • GE Life Sciences
    • Hybritech
    • Pall Corporation
    • Radiometer Medical ApS
    • HemoCue AB
    • Integrated DNA Technologies, Inc.
    • Leica Microsystems Inc.
    • Leica Biosystems Inc.
    • Vision Systems Ltd.
    • Coretech Holdings, LLC
    • Q3DM Inc.
    • Aldevron LLC
UsernamePublicRestriction

Register